

## **Foamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled for Tuesday, May 10**

REHOVOT, Israel, and BRIDGEWATER, New Jersey, April 26, 2017 /[PRNewswire](#)/ - Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report its financial results for the first quarter ended March 31, 2017 on Tuesday, May 9<sup>th</sup> after market close, and will host a corporate update conference call and webcast on Wednesday, May 10<sup>th</sup>, at 8:30am Eastern Time.

### ***Conference Call & Webcast***

***Tuesday, May 10, 2016 @ 8:30 am Eastern Time***

Toll Free: 888-438-5519

International: 719-457-1506

Conference ID: 2254081

Webcast: <http://public.viavid.com/index.php?id=124151>

*Replays, Available through May 24<sup>th</sup>:*

Toll-Free: 844-512-2921

International: 412-317-6671

Conference ID: 2254081

### ***About Foamix Pharmaceuticals Ltd.***

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.

Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFR1 anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.

For more information, please visit [www.foamixpharma.com](http://www.foamixpharma.com).

**Contact:**


Ilan Hadar, CFO  
LifeSci Advisors, LLC  
+972-8-9316233  
[ilan.hadar@foamixpharma.com](mailto:ilan.hadar@foamixpharma.com)

**US Investor Relations**

Michael Rice  
LifeSci Advisors, LLC  
+1-646-597-6979  
[mrice@lifesciadvisors.com](mailto:mrice@lifesciadvisors.com)

SOURCE Foamix Pharmaceuticals Ltd

---

Additional assets available online:  [Photos \(1\)](#)

<http://investors.foamixpharma.com/2017-04-26-Foamix-Pharmaceuticals-First-Quarter-Financial-Results-Conference-Call-Webcast-Scheduled-for-Tuesday-May-10>